CING vs CMMB

Cingulate Inc. vs Chemomab Therapeutics Ltd. — Valuation Comparison 2026

CING

Pharmaceutical Preparations
Cingulate Inc.
Quality
3.0
out of 10
Value Trap
39
LOW
Price
$4.16
Last close
Models
6/13
Active
VS

CMMB

Pharmaceutical Preparations
Chemomab Therapeutics Ltd.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$2.00
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CING Fair ValueCING Upside CMMB Fair ValueCMMB Upside
Bayesian DCF Intrinsic $1.90 -54.3% $0.44 -77.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.42 -41.8% $0.74 -62.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $0.10 -94.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CING vs CMMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CING vs CMMB — Which Stock Is More Undervalued?

CING scores higher with a 3.0/10 quality rating vs CMMB's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cingulate Inc. (CING) and Chemomab Therapeutics Ltd. (CMMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CING currently trades at $4.16 with a QOC of 3.0/10, while CMMB trades at $2.00 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).